Eli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in Value - The New York Times

kept by eddie nov 22, 25

Eli Lilly, the drugmaker behind Zepbound and Mounjaro, became the first health-care company to achieve a $1 trillion market value.

New Eli Lilly Drug Retatrutide Brought Major Weight Loss in Trial - The New York Times
A clinical trial of Eli Lilly's retatrutide, which targets three hormones, resulted in significantly greater weight loss than any currently approved drug.
also on Zepbound, Eli Lilly, #healthcare
Not For Human Consumption - by Somewhere - Vectorculture
Grey market peptides have built a parallel pharmaceutical infrastructure under the thinnest regulatory pretense, revealing a cultural contradiction beyond weight loss.
also on Eli Lilly